Work

Safety Profile of Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant

Year: 2009

Type: article

Abstract: We report here our experience with 105 pts with hematologic malignancies treated with busulfan (Bu) and fludarabine (Flu) as conditioning prior to allogeneic hematopoietic cell transplant. Bu was dosed at 100–145mg/m2/day on days 1 and 2 with pharmacokinetic targeting for days 3 and 4; the dose of Flu was 40mg/m2/day for 4 days. The median age was 47.6 years (range 22–67 years). Forty-one pts received grafts from matched siblings, 48 from matched URD, and 16 from URD mismatched at 1 antigen/allele.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2008.12.329